Federica Di Vincenzo

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Neurofeedback as a non-pharmacological strategy for pain and gut-brain axis disorders: clinical relevance in inflammatory bowel disease.

Neurofeedback as a non-pharmacological strategy for pain and gut-brain axis disorders: clinical relevance in inflammatory bowel disease.

Journal: Minerva gastroenterology

Published: June 17, 2026

Self-Care and Illness Perception in Inflammatory Bowel Disease: Identifying Adaptive and Maladaptive Profiles Through Person-Centered Analysis.

Self-Care and Illness Perception in Inflammatory Bowel Disease: Identifying Adaptive and Maladaptive Profiles Through Person-Centered Analysis.

Journal: The Psychiatric quarterly

Published: June 05, 2026

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.

Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: June 05, 2026

Agricultural chemicals and gut microbiota dysbiosis: implications for the pathogenesis of inflammatory bowel disease.

Agricultural chemicals and gut microbiota dysbiosis: implications for the pathogenesis of inflammatory bowel disease.

Journal: Frontiers in nutrition

Published: May 15, 2026

Rewriting Inflammation in IBD: Lipidomics from Pathogenesis to Clinical Application.

Rewriting Inflammation in IBD: Lipidomics from Pathogenesis to Clinical Application.

Journal: Microorganisms

Published: May 08, 2026

Timing of biologic prophylaxis and postoperative recurrence in Crohn's disease: A real-life cohort study using propensity score weighting.

Timing of biologic prophylaxis and postoperative recurrence in Crohn's disease: A real-life cohort study using propensity score weighting.

Journal: Inflammatory bowel diseases

Published: February 28, 2026

Adverse Childhood Experiences and Disease Activity Are Associated with Post-Traumatic Stress Symptoms in Crohn's Disease.

Adverse Childhood Experiences and Disease Activity Are Associated with Post-Traumatic Stress Symptoms in Crohn's Disease.

Journal: Advances in therapy

Published: February 10, 2026

Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology.

Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: January 19, 2026

Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology.

Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: January 19, 2026

Inflammatory bowel disease (IBD) is associated with increased intestinal extrachromosomal circular DNA: an emerging biomarker for IBD type and activity.

Inflammatory bowel disease (IBD) is associated with increased intestinal extrachromosomal circular DNA: an emerging biomarker for IBD type and activity.

Journal: Journal of Crohn's & colitis

Published: December 29, 2025

Effectiveness and safety of mirikizumab in ulcerative colitis: real-world data from the Latium Net.

Effectiveness and safety of mirikizumab in ulcerative colitis: real-world data from the Latium Net.

Journal: BMJ open gastroenterology

Published: December 23, 2025

Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.

Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.

Journal: The American journal of gastroenterology

Published: October 27, 2025

Showing 1-12 of 44

Last Updated: 09/26/2026